EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia iD und 3 weitere

Advanced Science · 2026-03 · 13 (13)

DOI: 10.1002/advs.202521623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.01.2026. Verfasst von Xiaopei Hao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan Province Outstanding Youth Project for Young and Middle-Aged Talents in Healthcare Scientific and Technological Innovation, National Key Clinical Discipline Construction Project, the Medical Sci-Tech Innovation Platform of Zhongnan Hospital of Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor‐engineered natural killer T (CAR‐NKT) cell therapy represents a promising and innovative strategy in cancer immunotherapy, but is limited by acute toxicity and adverse effects, restricting broader clinical application despite durable responses. In this study, a novel nanobody targeting TM4SF1 is developed, which replaced the conventional single‐chain variable fragment (scFv) in the design of CAR TM4SF1 ‐NKT cells. Moreover, CAR TM4SF1 ‐extracellular vesicles (EVs) therapy as an optimized alternative to direct CAR‐NKT cell administration is introduced. Compared with conventional CAR TM4SF1 engineered cells, CAR TM4SF1 ‐EVs demonstrated superior antitumor efficacy while significantly reducing toxicity. This findings revealed that CAR TM4SF1 ‐EVs selectively targeted TM4SF1‐expressing tumor cells in both in vitro and in vivo models. In hepatocellular carcinoma (HCC) mouse models, CAR TM4SF1 ‐EVs induced immunogenic cell death (ICD) and effectively suppressed tumor growth and metastasis. The therapeutic efficacy of CAR TM4SF1 ‐EVs is primarily attributed to their ability to remodel the immunosuppressive tumor microenvironment (TME), notably by enhancing CD8⁺ T cell activity and eliciting robust antitumor immune responses. Furthermore, CAR TM4SF1 ‐EVs synergized with Immune Checkpoint Blockade (ICB) therapy, leading to durable antitumor immune memory. Collectively, these findings establish CAR TM4SF1 ‐EVs therapy as a safe and effective strategy for targeted cancer immunotherapy, underscoring its potential for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesReceptors, Chimeric AntigenImmunotherapy, AdoptiveLiver NeoplasmsCarcinoma, HepatocellularKiller Cells, NaturalAnimalsMiceHumansTumor MicroenvironmentCell Line, Tumor

Stichwörter der Autor:innen

CAR‐NKTTM4SF1 nanobodycancer therapyextracellular vesiclesimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key laboratory of Hepatobiliary Cancers, Nanjing, 2100…
  • Department of Chemistry, Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL, 60637, USA.
  • Zhongnan Hospital of Wuhan University, TaiKang Center for Life and Medical Sciences, Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan Uni…
  • Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • Department of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.

ORCID-Profile: Peng Xia

Förderung

  • National Natural Science Foundation of China
  • Henan Province Outstanding Youth Project for Young and Middle-Aged Talents in Healthcare Scientific and Technological Innovation
  • National Key Clinical Discipline Construction Project, the Medical Sci-Tech Innovation Platform of Zhongnan Hospital of Wuhan University
  • Program of Excellent Doctor of Zhongnan Hospital of Wuhan University
  • China Postdoctoral Science Foundation General Program
  • Postdoctor Project of Hubei Province
  • Henan Provincial Science and Technology Research Project
  • Henan Provincial Science and Technology Project

Zitieren

APA

Hao, X., Qu, C., Zhou, Y., Wang, X., Qian, X., Chen, X., Han, F., Zhang, X., Ji, Y., Li, H., Ju, C., Xia, P., Tang, W., Zhuang, H., & Zhou, J. (2026). Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. Advanced Science, 13(13). https://doi.org/10.1002/advs.202521623

Vancouver

Hao X, Qu C, Zhou Y, Wang X, Qian X, Chen X, et al. Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. Advanced Science. 2026;13(13). doi:10.1002/advs.202521623

BibTeX
@article{Hao2026,
  author = {Hao, Xiaopei and Qu, Chengming and Zhou, Yanzhao and Wang, Xiaoqian and Qian, Xiangjun and Chen, Xun and Han, Feng and Zhang, Xiaokai and Ji, Yiyi and Li, Han and Ju, ChengWei and Xia, Peng and Tang, Weiwei and Zhuang, Hao and Zhou, Jinxue},
  title = {Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {13},
  doi = {10.1002/advs.202521623}
}
Kostenlos starten →